Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by StockNews.com to “Hold”

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also weighed in on the company. Cantor Fitzgerald cut their target price on Ascendis Pharma A/S from $173.00 to $170.00 and set an “overweight” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. cut their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday. Citigroup decreased their target price on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating for the company in a report on Wednesday. TD Cowen lowered their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a report on Wednesday. Finally, The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $187.08.

Ascendis Pharma A/S Price Performance

ASND stock traded down $0.50 on Thursday, hitting $119.00. 817,826 shares of the company were exchanged, compared to its average volume of 392,208. The stock has a market capitalization of $6.93 billion, a price-to-earnings ratio of -12.38 and a beta of 0.63. The business’s fifty day moving average is $134.73 and its two-hundred day moving average is $138.46. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently modified their holdings of ASND. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the 1st quarter worth approximately $36,000. Quadrant Capital Group LLC grew its stake in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 91 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at about $126,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.